Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2020-07-01 / Discov Med 2020 Jul-Aug;30(159):39-48Hyperthermia treatment advances for brain tumors
/in Glioblastoma, Hyperthermia, International Publications /von 2020-07-01 / Int J Hyperthermia 2020 07;37(2):3-19Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646State-of-the-art exosome loading and functionalization techniques for enhanced therapeutics: a review
/in International Publications /von 2020-06-30 / Crit. Rev. Biotechnol. 2020 Sep;40(6):804-820Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2020-06-29 / Cancer Cell Int. 2020;20:278Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-06-27 / Virusdisease 2020 Sep;31(3):341-348CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model
/in Dendritic Cells, Glioblastoma, International Publications /von 2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-303Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2020-06-21 / J Control Release 2020 Jun;326:63-74Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy
/in Dendritic Cells, International Publications /von 2020-06-15 / Nanomedicine 2020 Jun;29:102240
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de